Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 5:01 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 150 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Ocular Pain Clear all
Completed Phase 3 Interventional Results available

A Phase 3 Study Evaluating the Efficacy and Safety of OCS-01 Eyedrops Compared to Vehicle for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery

NCT05147233
View directory record Official record
Conditions
Inflammation Eye Pain, Postoperative Cataract
Interventions
OCS-01, Vehicle
Drug
Lead sponsor
Oculis
Industry
Eligibility
18 Years and older
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
25
States / cities
Chandler, Arizona • Phoenix, Arizona • Fayetteville, Arkansas + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2025 · Synced Jul 22, 2026, 5:01 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Safety, Systemic Pharmacokinetics, and Tolerability

NCT03063489
View directory record Official record
Conditions
Eye Pain
Interventions
Loteprednol Etabonate Ophthalmic Gel
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
6
States / cities
Phoenix, Arizona • Oceanside, California • Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Jul 22, 2026, 5:01 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate ISV-305 Compared to Vehicle for Treatment of Inflammation and Pain Associated With Cataract Surgery

NCT03192137
View directory record Official record
Conditions
Inflammation and Pain Associated With Cataract Surgery
Interventions
ISV-305, Vehicle
Drug · Other
Lead sponsor
Sun Pharmaceutical Industries Limited
Industry
Eligibility
17 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 18, 2021 · Synced Jul 22, 2026, 5:01 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Can Virtual Reality Reduce Pain and Anxiety During Blood Draw

NCT04449341
View directory record Official record
Conditions
Procedural Anxiety, Procedural Pain
Interventions
Oculus Go headset with Ocean Rift application
Device
Lead sponsor
C.R.Darnall Army Medical Center
Federal
Eligibility
18 Years to 50 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Fort Hood, Texas
Source: ClinicalTrials.gov public record
Updated Jul 12, 2021 · Synced Jul 22, 2026, 5:01 AM EDT
Recruiting Phase 2 Interventional

Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)

NCT02521311
View directory record Official record
Conditions
Optic Neuritis
Interventions
Clemastine, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 55 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Jul 22, 2026, 5:01 AM EDT
Terminated Not applicable Interventional Results available

Spectacle Tints and Thin-Films for Migraine

NCT02720211
View directory record Official record
Conditions
Headache Migraine Chronic
Interventions
Gray tinted spectacle lenses, Thin-Film spectacle lenses
Device
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 60 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
4
States / cities
Phoenix, Arizona • Boston, Massachusetts • Great Neck, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2022 · Synced Jul 22, 2026, 5:01 AM EDT
Completed No phase listed Observational

Quality of Life in Younger Leukemia and Lymphoma Survivors

NCT00956475
View directory record Official record
Conditions
Anxiety Disorder, Cancer Survivor, Fatigue, Leukemia, Long-term Effects Secondary to Cancer Therapy in Adults, Lymphoma, Lymphoproliferative Disorder, Pain, Psychosocial Effects of Cancer and Its Treatment, Small Intestine Cancer
Interventions
telephone-based intervention, questionnaire administration, assessment of therapy complications, fatigue assessment and management, psychosocial assessment and care, quality-of-life assessment
Behavioral · Other · Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years to 35 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 23, 2011 · Synced Jul 22, 2026, 5:01 AM EDT
Terminated Phase 4 Interventional Results available

Azithromycin for Meibomian Gland Disease

NCT03953118
View directory record Official record
Conditions
Dry Eye, Neuropathic Eye Pain, Ocular Microbiome, Depression, Anxiety
Interventions
Azithromycin Oral Product, Placebo Oral
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Jul 22, 2026, 5:01 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Intravitreal Injection Site and Perceived Pain

NCT05640895
View directory record Official record
Conditions
Pain
Interventions
Intravitreal injection site
Procedure
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years to 100 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 30, 2025 · Synced Jul 22, 2026, 5:01 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Post Photorefractive Keratectomy (PRK) Use of an Eye Shield for Maintaining Vision and Mitigating Pain

NCT01592643
View directory record Official record
Conditions
Pain, Vision Nearsighted
Interventions
Eye Shield
Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Dec 21, 2021 · Synced Jul 22, 2026, 5:01 AM EDT
Terminated Phase 3 Interventional

Study Evaluating the Efficacy and Safety of OCS-01 Eye Drops in Subjects Following Cataract Surgery

NCT06128369
View directory record Official record
Conditions
Inflammation Eye, Pain, Postoperative, Cataract
Interventions
Dexamethasone Ophthalmic Suspension, Vehicle of OCS-01
Drug · Other
Lead sponsor
Oculis
Industry
Eligibility
18 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
12
States / cities
Inglewood, California • Morrow, Georgia • Louisville, Kentucky + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2024 · Synced Jul 22, 2026, 5:01 AM EDT
Completed Phase 2 Interventional Results available

Study of SAF312 as an Eye Drop for Treatment of Eye Pain Following Photorefractive Keratectomy (PRK) Surgery

NCT02961062
View directory record Official record
Conditions
Postoperative Ocular Pain After PRK Surgery
Interventions
SAF312, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
4
States / cities
Chevy Chase, Maryland • Sioux Falls, South Dakota • Draper, Utah + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2021 · Synced Jul 22, 2026, 5:01 AM EDT
Recruiting Not applicable Interventional

Randomized Controlled Trial of the STEIN Protocol: A Neuroplastic Pain Education and Guided Breathing Intervention During Awake Cataract Surgery

NCT07715591
View directory record Official record
Conditions
Cataract, Cataract (Post-operative Cataract Surgery Follow-up)
Interventions
Music and Guided Imagery, Control, Music Only
Device
Lead sponsor
University of California, Los Angeles
Other
Eligibility
Not listed
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Jul 22, 2026, 5:01 AM EDT
Terminated Not applicable Interventional Results available

Intranasal Neurostimulation in Ameliorating Symptoms of Neuropathic Corneal Pain

NCT03674892
View directory record Official record
Conditions
Cornea
Interventions
TrueTear™ intranasal neurostimulator (ITN)
Device
Lead sponsor
Tufts Medical Center
Other
Eligibility
22 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 23, 2025 · Synced Jul 22, 2026, 5:01 AM EDT
Completed Not applicable Interventional Results available

Anesthesia Preference for Intravitreal Injection: Topical or Subconjunctival

NCT01640171
View directory record Official record
Conditions
Age-related Macular Degeneration, Central Retinal Vein Occlusion, Diabetic Macular Edema
Interventions
Xylocaine 2% Injectable Anesthetic, Proparacaine Hydrochloride 0.5% Drop, Tetravisc 0.5% Gel, Acuvail, Intra-vitreal Anti-VEGF Drug
Procedure · Drug
Lead sponsor
Retina Vitreous Associates of Florida
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Clearwater, Florida
Source: ClinicalTrials.gov public record
Updated Apr 20, 2014 · Synced Jul 22, 2026, 5:01 AM EDT
Completed No phase listed Observational

Smarter Care Virginia, Examining Low-Value Care in Virginia

NCT04053335
View directory record Official record
Conditions
Chronic Kidney Diseases, Eye Diseases, Cardiac Disease, Surgery, Low Back Pain
Interventions
Multicomponent Physician Performance Peer-Comparison Feedback Intervention
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
5,000,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 2, 2023 · Synced Jul 22, 2026, 5:01 AM EDT
Completed Phase 2 Interventional

A Study of MELT-300 (Midazolam and Ketamine Sublingual Tablets) for Sedation and Intraoperative Ocular Analgesia in Participants Undergoing Cataract Extraction With Lens Replacement (CELR)

NCT05133518
View directory record Official record
Conditions
Cataract
Interventions
MELT-300, Midazolam alone, Ketamine alone, Placebo
Drug
Lead sponsor
Melt Pharmaceuticals
Industry
Eligibility
55 Years and older
Enrollment
338 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
3
States / cities
Rancho Cordova, California • Jacksonville, Florida • West Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Dec 18, 2022 · Synced Jul 22, 2026, 5:01 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Multi-modal Imaging of Myofascial Pain

NCT06036524
View directory record Official record
Conditions
Myofascial Pain
Interventions
Multi-modal, multi-parametric, multiscale imaging of the myofascial unit
Diagnostic Test
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 80 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Jul 22, 2026, 5:01 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Cool vs Room-temperature Artificial Tears

NCT05832996
View directory record Official record
Conditions
Diabetic Retinopathy With Macular Edema of Both Eyes (Diagnosis), Central Retinal Vein Occlusion With Macular Edema, Exudative Age-Related Macular Degeneration, Unspecified Eye, Cystoid Macular Edema, Ocular Surface Disease, Dry Eye Sensation, Eye Pain
Interventions
Refresh Plus Preservative-free Lubricant Eye Drops
Drug
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 105 Years
Enrollment
124 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Mar 3, 2025 · Synced Jul 22, 2026, 5:01 AM EDT
Completed Phase 2 Interventional Results available

Study of Efficacy and Safety of SAF312 Eye Drops in Subjects With Post-operative Corneal Induced Chronic Pain (CICP)

NCT04630158
View directory record Official record
Conditions
Chronic Ocular Pain
Interventions
SAF312 Placebo, SAF312
Other · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
24
States / cities
Mission Hills, California • Newport Beach, California • Palo Alto, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Jul 22, 2026, 5:01 AM EDT
Completed Phase 3 Interventional Results available

2nd Study to Assess ISV-305 Compared to Vehicle for Treatment of Inflammation and Pain Associated With Cataract Surgery

NCT03192150
View directory record Official record
Conditions
Inflammation and Pain Associated With Cataract Surgery
Interventions
ISV-305, Vehicle
Drug · Other
Lead sponsor
Sun Pharmaceutical Industries Limited
Industry
Eligibility
17 Years and older
Enrollment
246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 18, 2021 · Synced Jul 22, 2026, 5:01 AM EDT
Completed Phase 2 Interventional Results available

High Frequency Impulse Therapy for Neuropathic Pain in NMOSD

NCT04614454
View directory record Official record
Conditions
Neuromyelitis Optica
Interventions
High Frequency Impulse Therapy, High Frequency Impulse Therapy - Sham
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Jul 22, 2026, 5:01 AM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate Efficacy and Safety of MELT-300 for Procedural Sedation in Subjects Undergoing Cataract Extraction With Lens Replacement (CELR)

NCT06383273
View directory record Official record
Conditions
Cataract
Interventions
MELT-300 sublingual tablet, Midalozam sublingual tablet, Placebo sublingual tablet
Drug
Lead sponsor
Melt Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
528 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
12
States / cities
Chico, California • Grand Junction, Colorado • Jacksonville, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2024 · Synced Jul 22, 2026, 5:01 AM EDT
Completed Phase 3 Interventional Results available

Loteprednol Etabonate Ophthalmic Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery

NCT02208297
View directory record Official record
Conditions
Inflammation, Pain, Cataract
Interventions
Loteprednol Etabonate Gel (BID), Vehicle Gel (BID)
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
326 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 24, 2020 · Synced Jul 22, 2026, 5:01 AM EDT